Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

COSMOS Pharmaceutical (3349.T)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (¥) Price Target (¥) Rating
2022-02-2879358750Neutral
2022-03-2578658250Neutral
2022-08-1073007750Neutral
2023-02-0864807000Neutral
2023-09-207855-No Rating
2023-10-3075458235Neutral
2023-12-0883458570Neutral
2024-01-1379108415Neutral
2024-04-1370207720Neutral
2024-06-1164887205Neutral
2024-07-1364087025Neutral
2024-09-1173197400Neutral
2024-09-2772527710Neutral
2024-10-1273207870Neutral
2024-12-1070537780Neutral
2025-01-1574867920Neutral
2025-03-2574387840Neutral
2025-04-1584548810Neutral

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.